Table 1

T cell-depleted and unmanipulated haploidentical stem cell transplantation

Centers (year)

Disease

No. of pts

Conditioning

GVHD prophylaxis

Cell dose 10⁶/kg

TCD methods

Graft failure

Acute GVHD

Chronic GVHD

TRM

Relapse

DFS

CD34

CD3

T-cell depleted

Perugia, Italy

1994[16]

AML/ALL/CML

36

TBI/TT/CY/ATG

Extensive TCD

10.8

0.22

Lectin-based+E-rosette

1/17

1/16

0/9

9/17

2/17

6/17

USC, USA

1997[12]

AML/ALL

72

TBI/VP16/Ara-C/CY/ATG

Partial TCD

CSP, MP, ATG

1.36

0.075

Ex vivo TCD with T10B9

2%

16%

35%

65.3%

32%

2-year OS

55% for SR

27% for HR

Perugia, Italy

1998[17]

AML

ALL

44

TBI/TT/F/ATG

Extensive TCD

10.5

0.02

Ex vivo CD34 selection

5%

0

0

40%

13%

63%

36%

17%

Boston, USA

1999[40]

AML/ALL/NHL/others

12

TBI/Ara-c/CY

CTLA4-Ig, CSP+MTX

2.2

28

CTLA4-Ig,

1/11

3/11

1/11

7/12

1/12

5/12

Multicenter, Japan

2000[61]

Leukemia/others

135

TBI-based

CSP/Tac/MTX/Steroids

3.2

5.5

4.9

0.06(M)

0.09(P)

0.01(M+P)

Ex vivo CD34+ selection

13%

II~IV

21%

35%

47%

22%for SR

79%for HR

5-year

39% for SR

5% for HR

Tuebingen, Germany

2004[22]

AML/ALL/others

63

TBI or Bu-based with F/TT/ATG/Cy

Extensive TCD

19.5

0.011

Ex vivo CD34/CD133 selection

17%

II 7%

13%

28%

30%

3-year

48% (ALL/NHL)

USC, USA

2004[13]

AML/ALL

201

TBI/VP16/Ara-C/Cy/ATG

Partial TCD

CSP, MP, ATG

1.9

0.05

Ex vivo TCD with T10B9/OKT3

2%

13%

15%

51%

31%

5-year 18%

Multicenter, Canada,

2004[62]

AML

11

Mel/TT/F/ATG

TCD

13.7

0.005

Ex vivo CD34 selection

0%

0%

NA

55%

37%

9-month 9%

Perugia, Italy

2005[18,21]

AML/ALL/CML

175

TBI/TT/F/ATG

Extensive TCD

12.8

0.01

Ex vivo CD34 selection

6%

II~IV 8%

4%

36.5%

24% for AML

27% for ALL

5-year

47% in CR

4% in rel

Tuebingen, Germany

2007[25]

HM/AA

38

F/TT/Mel/OKT3

TCD

16

0.049

CD3/CD19 negative selection

17%

II~IV 27%

2.6%

70% for SR

20% for HR

Multicenter, Germany

2008[24]

HM

29

F/TT/Mel/OKT3

TCD

7.6

0.044

CD3/CD19 negative selection

0%

II~IV 48%

3/29

8/29

41%

1-year 35%

Non-T-cell depleted

Jone-Hopkins University

2004[37]

Leukemia/MDS

56

F/CY/TBI(2 Gy)

Tac/MMF/CY

NA

NA

Not done

17%

66%

NR

9%(d100)

NA

1-year 38%

Beijing, China

2006[11]

ALL/AML/CML/MDS

171

Bu/Ara-C/CY/Me-CCNU/ATG

CSP/MMF/MTX short

1.8

220

Not done

0

55%

47%

2-year

19% for SR

31% for HR

12% for SR

39% for HR

2-year

68% for SR

42% for HR

Japan, 2006[39]

Leukemia/lymphoma

26

F/Bu/ATG

Tac/MP

6.55

254

In vitro TCD with ATG

4%

19%

25%

15% (d100)

3-year 61%

Duke University, USA

2007[38]

Leukemia/MDS/MPD

49

F/CY/Alemtuzumab

MMF ± CSP

Partial TCD

13.5

460

In vivo ± ex vivo TCD/Alemtuzumab

14%

16%

14%

31%

49%

1-year 43%

*AML = acute myeloid leukemia; ALL = acute lymphoid leukemia; Ara-C = cytarabine; ATG = anti-thymocyte globulin; BU = busulfan; CML = chronic myeloid leukmemia; CR = complete remission; CSP = cyclosporine A; CY = cyclophosphamide; DFS = disease free survival; F = fludarabine; GVHD = graft versus host disease; HM = hematologic malignancies; HR = high risk; MDS = myelodysplastic syndrome; Mel = melphalan; MMF = mycophenolate mofetil; MP = methylprednisolone; MTX = methotrexate; NA = not available; NHL = non-Hodgkin lymphoma; OS = overall survival; pts = patients; rel = relapse; SR = standard risk; Tac = tacrolimus; TBI = total body irradiation; TCD = T-cell depletion; TRM = transplant related motality; TT = thiotepa.

Huang Journal of Hematology & Oncology 2008 1:27   doi:10.1186/1756-8722-1-27